About
DEINOVE (Euronext Growth Paris: ALDEI) is a biotech company that discovers, develops and produces high added-value compounds from rare microorganisms for use in the fields of health, nutrition and cosmetic markets. To do so, DEINOVE draws on two key assets: • a unique library of 6,000 rare or unexploited...
DEINOVE (Euronext Growth Paris: ALDEI) is a biotech company that discovers, develops and produces high added-value compounds from rare microorganisms for use in the fields of health, nutrition and cosmetic markets. To do so, DEINOVE draws on two key assets: • a unique library of 6,000 rare or unexploited bacterial strains; • a genetic, metabolic and fermentation engineering platform capable of customizing these natural "micro-factories" to transform them into new industrial standards. Based in Montpellier, DEINOVE employs approximately 55 employees and has nearly 160 international patents. The Company has been listed on Euronext Growth since April 2010.
  • 9
    Jul
    18
    News Release
    Deinove awarded by the bioeconomy community
  • 28
    Jun
    18
    News Release
    Deinove enters into collaboration with bioMérieux to discover new antibiotics
  • 19
    Jun
    18
    Equity Research
    Deinove SA (EPA:ALDEI) Research Initiation
  • 19
    Jun
    18
    News Release
    Arrowhead initiates coverage on Deinove in the United States
  • 15
    Jun
    18
    News Release
    DEINOVE: Successful Capital Increase of € 8.5 Million
  • 14
    Jun
    18
    News Release
    DEINOVE announces the launch of a capital increase through an accelerated book building
  • 30
    May
    18
    News Release
    DEINOVE and OLEOS expand their collaboration with the support of the Occitanie Region
  • 23
    May
    18
    News Release
    DEINOVE General meeting of May 23: Shareholders approve the acquisition of MORPHOCHEM
  • 22
    May
    18
    News Release
    DEINOVE COLOR2B project: confirmed progress and outlook
  • 30
    Apr
    18
    Company Presentation
    DEINOVE Presentation to Investors - Update on Antibiotic strategy
  • 16
    Apr
    18
    News Release
    DEINOVE and GREENTECH announce the launch of HEBELYS®, the first cosmetic active ingredient resulting from their collaboration
  • 13
    Apr
    18
    News Release
    DEINOVE takes on a whole new dimension with the acquisition of MORPHOCHEM’s clinical-stage antibiotic compound
  • 10
    Apr
    18
    News Release
    DEINOVE introduces Phyt-n-Resist®, the first pure phytoene for skincare
  • 29
    Mar
    18
    News Release
    DEINOVE 2017: ambitions confirmed, milestones reached, and financial results in line with the development strategy
  • 22
    Mar
    18
    News Release
    DEINOVE expands its innovative antibiotic portfolio by signing a license option agreement with REDX PHARMA
  • 8
    Mar
    18
    News Release
    DEINOVE collaborates with NAICONS to discover new antibiotics in the frame of the AGIR project
  • 26
    Feb
    18
    News Release
    DEINOVE announces the success of its cosmetic active ingredient’s production process industrialization
  • 19
    Feb
    18
    News Release
    DEINOVE announces its financial calendar for 2018
  • 30
    Jan
    18
    News Release
    DEINOVE and Hallstar’s Oléos, partners in the development of a new cosmetic active ingredient
  • 18
    Dec
    17
    News Release
    DEINOVE launches the industrial production of its first carotenoid
  • 20
    Nov
    17
    News Release
    DEINOVE and GREENTECH are making progress in the co-development of their cosmetic active ingredient
  • 31
    Oct
    17
    Company Presentation
    DEINOVE Presentation to Investors, October 2017
  • 23
    Oct
    17
    News Release
    DEINOVE confirms the launch of its first cosmetic active ingredient during the first half of 2018 and targets the very dynamic segment of anti-aging skincare
  • 28
    Sep
    17
    News Release
    DEINOVE 2017 half-year consolidated results: stability of net loss major progress on R&D programs in health, nutrition and cosmetics
  • 28
    Sep
    17
    Corporate Update
    DEINOVE Interim financial report – Half-year 2017
  • 12
    Sep
    17
    News Release
    The AGIR project carried out by the DEINOVE group is granted €14.6 million by the ‘Investments for the Future’ Program (IFP) operated by Bpifrance to develop new antibiotics
  • 24
    Jul
    17
    News Release
    DEINOVE strengthens its Business Development activity with the arrival of Sébastien Enault
  • 5
    Jul
    17
    News Release
    DEINOVE: the industrialization process of the carotenoids program enters phase II
  • 31
    May
    17
    News Release
    DEINOVE and FLINT HILLS RESOURCES enter the second stage of their partnership in animal feed
  • 23
    May
    17
    News Release
    DEINOVE welcomes its new Director of R&D, Georges Gaudriault
  • 16
    May
    17
    News Release
    DEINOVE Shareholders’ meeting of May 16, 2017: Hervé BRAILLY joins the Board of Directors
  • 30
    Mar
    17
    Corporate Update
    DEINOVE Annual Financial Report 2016